在患有心血管疾病的甲基胺使用者中,β阻断剂治疗的结果
Anna Bjarvin1, Sydney Cross1, Stone Holtzman1
1Western University of Health Sciences College of Osteopathic Medicine of the Pacific, Woodinville, WA, USA.
概括
β-阻断剂,特别是卡维迪醇,对于治疗甲基胺使用者的高血压是安全有效的. 这项研究发现,接受β-阻断剂的患者的住院时间或再入院率没有增加.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲基胺使用经常导致心血管问题,如高血压和心力衰竭.
- 临床医生在甲基胺中毒时经常避免服用β抑制剂,因为担心无对立的α刺激和加剧的高血压.
研究的目的:
- 评估贝塔抑制剂在甲基胺中毒患者中使用的安全性和有效性.
- 为了比较接受β-阻断剂的甲基胺使用者与不接受β-阻断剂的使用者之间的结果.
主要方法:
- 从加利福尼亚州县医院的医疗记录的回顾性审查.
- 纳入标准:成年人甲胺检测阳性,在48小时内接受β-阻断剂治疗 (病例组) 或非β-阻断剂抗高血压剂/没有抗高血压剂 (对照组).
- 住院时间,30天再入院率,入院时的血压 (心压和心压) 和24小时的血压的比较.
主要成果:
- 在beta-blocker和对照组之间,停留时间或30天再接收率没有显著差异.
- 在甲基胺诱导的高血压患者中,卡维迪洛在24小时内有效降低了缩血压,而与对照组相比,停留时间没有显著差异.
- 贝塔抑制剂治疗没有增加停留时间或再入院率.
结论:
- 贝塔抑制剂是一种安全有效的治疗选择,用于甲基胺使用者的心血管疾病.
- 卡维迪洛尔在管理与甲基胺使用相关的高血压方面表现出有效性,包括甲基胺诱导的心肌病.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
543
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
543
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
01:28Antihypertensive Drugs: Types of β-Blockers
603
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
603
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
420
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
420
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:17Antihypertensive Drugs: Action of β1 Blockers
320
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
320